Neoadjuvant Chemotherapy
Conditions
Keywords
operable breast cancer, skeletal mass index, neoadjuvant chemotherapy, pathologic response, L3 vertebra
Brief summary
The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
Detailed description
In patients with operable breast cancer (BC) receiving neoadjuvant chemotherapy (NAC), the pathological response rate was found to be related to body composition. The success of complete pathologic response (pCR) is a known prognostic factor in BC patients treated with NAC. The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
Interventions
OTHERNeoadjuvant therapy
To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
Sponsors
Acıbadem Atunizade Hospital
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
29 Years to 72 Years
Inclusion criteria
* Early and locally advanced operated breast cancer patients receiving neoadjuvant chemotherapy.
Exclusion criteria
* Patients who did not receive neoadjuvant chemotherapy, had metastatic breast cancer and whose radiological images were not available.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sarcopenic index | Through study completion, an average of 1 year. | skeletal muscle area (cm2)/height (m2) et L3 level |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body mass index | Through study completion, an average of 1 year. | weight (kg)/height (m2) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Residual cancer burden | Through study completion, an average of 1 year. | Residual cancer burden (RCB) is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. |
Countries
Turkey (Türkiye)
Outcome results
None listed